16843263 |
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Wang, SE,
Narasanna, A,
Perez-Torres, M,
Xiang, B,
Wu, FY,
Yang, S,
Carpenter, G,
Gazdar, AF,
Muthuswamy, SK,
Arteaga, CL
|
Cancer Cell |
2006 |
18413839 |
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Trowe, T,
Boukouvala, S,
Calkins, K,
Cutler, RE,
Fong, R,
Funke, R,
Gendreau, SB,
Kim, YD,
Miller, N,
Woolfrey, JR,
Vysotskaia, V,
Yang, JP,
Gerritsen, ME,
Matthews, DJ,
Lamb, P,
Heuer, TS
|
Clin. Cancer Res. |
2008 |
26375550 |
Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
Hu, Z,
Hu, Y,
Liu, X,
Xi, R,
Zhang, A,
Liu, D,
Xie, Q,
Chen, L
|
Oncotarget |
2015 |
22046346 |
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib
Kancha, RK,
von Bubnoff, N,
Bartosch, N,
Peschel, C,
Engh, RA,
Duyster, J
|
PLoS ONE |
2011 |
25994018 |
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
Ng, CK,
Martelotto, LG,
Gauthier, A,
Wen, HC,
Piscuoglio, S,
Lim, RS,
Cowell, CF,
Wilkerson, PM,
Wai, P,
Rodrigues, DN,
Arnould, L,
Geyer, FC,
Bromberg, SE,
Lacroix-Triki, M,
Penault-Llorca, F,
Giard, S,
Sastre-Garau, X,
Natrajan, R,
Norton, L,
Cottu, PH,
Weigelt, B,
Vincent-Salomon, A,
Reis-Filho, JS
|
Genome Biol. |
2015 |
26545934 |
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations
Suzawa, K,
Toyooka, S,
Sakaguchi, M,
Morita, M,
Yamamoto, H,
Tomida, S,
Ohtsuka, T,
Watanabe, M,
Hashida, S,
Maki, Y,
Soh, J,
Asano, H,
Tsukuda, K,
Miyoshi, S
|
Cancer Sci. |
2016 |
25853726 |
Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity
Hu, Z,
Wan, X,
Hao, R,
Zhang, H,
Li, L,
Li, L,
Xie, Q,
Wang, P,
Gao, Y,
Chen, S,
Wei, M,
Luan, Z,
Zhang, A,
Huang, N,
Chen, L
|
PLoS ONE |
2015 |
28274957 |
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
Hanker, AB,
Brewer, MR,
Sheehan, JH,
Koch, JP,
Sliwoski, GR,
Nagy, R,
Lanman, R,
Berger, MF,
Hyman, DM,
Solit, DB,
He, J,
Miller, V,
Cutler, RE,
Lalani, AS,
Cross, D,
Lovly, CM,
Meiler, J,
Arteaga, CL
|
Cancer Discov |
2017 |
23948973 |
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2
Rexer, BN,
Ghosh, R,
Narasanna, A,
Estrada, MV,
Chakrabarty, A,
Song, Y,
Engelman, JA,
Arteaga, CL
|
Clin. Cancer Res. |
2013 |
30301790 |
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Cocco, E,
Javier Carmona, F,
Razavi, P,
Won, HH,
Cai, Y,
Rossi, V,
Chan, C,
Cownie, J,
Soong, J,
Toska, E,
Shifman, SG,
Sarotto, I,
Savas, P,
Wick, MJ,
Papadopoulos, KP,
Moriarty, A,
Cutler, RE,
Avogadri-Connors, F,
Lalani, AS,
Bryce, RP,
Chandarlapaty, S,
Hyman, DM,
Solit, DB,
Boni, V,
Loi, S,
Baselga, J,
Berger, MF,
Montemurro, F,
Scaltriti, M
|
Sci Signal |
2018 |
23220880 |
Activating HER2 mutations in HER2 gene amplification negative breast cancer
Bose, R,
Kavuri, SM,
Searleman, AC,
Shen, W,
Shen, D,
Koboldt, DC,
Monsey, J,
Goel, N,
Aronson, AB,
Li, S,
Ma, CX,
Ding, L,
Mardis, ER,
Ellis, MJ
|
Cancer Discov |
2013 |